Although augmented prostaglandin E 2 (PGE 2 ) synthesis and accumulation have been demonstrated in the lesion sites of rodent transient focal ischemia models, the role of PGE 2 in neuronal survival has been controversial, showing both protective and toxic effects. Here we demonstrate the induction of microsomal PGE synthase 1 (mPGES-1), an inducible terminal enzyme for PGE 2 synthesis, in neurons, microglia, and endothelial cells in the cerebral cortex after transient focal ischemia. In mPGES-1 knockout (KO) mice, in which the postischemic PGE 2 production in the cortex was completely absent, the infarction, edema, apoptotic cell death, and caspase-3 activation in the cortex after ischemia were all reduced compared with those in wild-type (WT) mice. Furthermore, the behavioral neurological dysfunctions observed after ischemia in WT mice were significantly ameliorated in KO mice. The ameliorated symptoms observed in KO mice after ischemia were reversed to almost the same severity as WT mice by intracerebroventricular injection of PGE 2 into KO mice. Our observations suggest that mPGES-1 may be a critical determinant of postischemic neurological dysfunctions and a valuable therapeutic target for treatment of human stroke.
Preconditioning (PC) using a preceding sublethal ischemic insult is an attractive strategy for protecting neurons by inducing ischemic tolerance in the brain. Although the underlying molecular mechanisms have been extensively studied, almost all studies have focused on neurons. Here, using a middle cerebral artery occlusion model in mice, we show that astrocytes play an essential role in the induction of brain ischemic tolerance. PC caused activation of glial cells without producing any noticeable brain damage. The spatiotemporal pattern of astrocytic, but not microglial, activation correlated well with that of ischemic tolerance. Interestingly, such activation in astrocytes lasted at least 8 weeks. Importantly, inhibiting astrocytes with fluorocitrate abolished the induction of ischemic tolerance. To investigate the underlying mechanisms, we focused on the P2X7 receptor as a key molecule in astrocyte-mediated ischemic tolerance. P2X7 receptors were dramatically upregulated in activated astrocytes. PC-induced ischemic tolerance was abolished in P2X7 receptor knock-out mice. Moreover, our results suggest that hypoxia-inducible factor-1α, a well known mediator of ischemic tolerance, is involved in P2X7 receptor-mediated ischemic tolerance. Unlike previous reports focusing on neuron-based mechanisms, our results show that astrocytes play indispensable roles in inducing ischemic tolerance, and that upregulation of P2X7 receptors in astrocytes is essential.
Microsomal prostaglandin E2 synthase (mPGES)‐1 is an inducible protein recently shown to be an important enzyme in inflammatory prostaglandin E2 (PGE2) production in some peripheral inflammatory lesions. However, in inflammatory sites in the brain, the induction of mPGES‐1 is poorly understood. In this study, we demonstrated the expression of mPGES‐1 in the brain parenchyma in a lipopolysaccharide (LPS)‐induced inflammation model. A local injection of LPS into the rat substantia nigra led to the induction of mPGES‐1 in activated microglia. In neuron‐glial mixed cultures, mPGES‐1 was co‐induced with cyclooxygenase‐2 (COX‐2) specifically in microglia, but not in astrocytes, oligodendrocytes or neurons. In microglia‐enriched cultures, the induction of mPGES‐1, the activity of PGES and the production of PGE2 were preceded by the induction of mPGES‐1 mRNA and almost completely inhibited by the synthetic glucocorticoid dexamethasone. The induction of mPGES‐1 and production of PGE2 were also either attenuated or absent in microglia treated with mPGES‐1 antisense oligonucleotide or microglia from mPGES‐1 knockout (KO) mice, respectively, suggesting the necessity of mPGES‐1 for microglial PGE2 production. These results suggest that the activation of microglia contributes to PGE2 production through the concerted de novo synthesis of mPGES‐1 and COX‐2 at sites of inflammation of the brain parenchyma.
Signaling through GABAAreceptors controls neural progenitor cell (NPC) developmentin vitroand is altered in schizophrenic and autistic individuals. However, thein vivofunction of GABAAsignaling on neural stem cell proliferation, and ultimately neurogenesis, remains unknown. To examine GABAAfunctionin vivo, we electroporated plasmids encoding short-hairpin (sh) RNA against the Na-K-2Cl cotransporter NKCC1 (shNKCC1) in NPCs of the neonatal subventricular zone in mice to reduce GABAA-induced depolarization. Reduced GABAAdepolarization identified by a loss of GABAA-induced calcium responses in most electroporated NPCs led to a 70% decrease in the number of proliferative Ki67+NPCs and a 60% reduction in newborn neuron density. Premature loss of GABAAdepolarization in newborn neurons resulted in truncated dendritic arborization at the time of synaptic integration. However, by 6 weeks the dendritic tree had partially recovered and displayed a small, albeit significant, decrease in dendritic complexity but not total dendritic length. To further examine GABAAfunction on NPCs, we treated animals with a GABAAallosteric agonist, pentobarbital. Enhancement of GABAAactivity in NPCs increased the number of proliferative NPCs by 60%. Combining shNKCC1 and pentobarbital prevented the shNKCC1 and the pentobarbital effects on NPC proliferation, suggesting that these manipulations affected NPCs through GABAAreceptors. Thus, dysregulation in GABAAdepolarizing activity delayed dendritic development and reduced NPC proliferation resulting in decreased neuronal density.